Vimarsana
Biggest News Aggregation in the World

Page 2 - Morphic Therapeutic News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphic Therapeutic. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphic Therapeutic Today - Breaking & Trending Today

AI-enhanced drug design software enters early access program - Vimarsana News

AI-enhanced drug design software enters early access program

DeepMirror, a University of Cambridge spin-out, introduces its Early Access Programme for intuitive design software dedicated to discovering innovative therapeutic drugs. Click to read more...

Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032) - Vimarsana News

Primary Sclerosing Cholangitis Market to Grow at a Tremendous CAGR of 17.2% During the Study Period (2019-2032)

/PRNewswire/ -- DelveInsight's Primary Sclerosing Cholangitis Market Insights report includes a comprehensive understanding of current treatment practices,...

Morphic Holdings Announces CEO Dr. Praveen Tipirneni to - Vimarsana News

Morphic Holdings Announces CEO Dr. Praveen Tipirneni to

WALTHAM, Mass., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Morphic Holdings Inc. (Nasdaq: MORF) today announced that Chief Executive Officer Dr. Praveen...

Morphic Therapeutic's Stock Plunges On Monday - Here's Why? - Morphic Holding (NASDAQ:MORF) - Vimarsana News

Morphic Therapeutic's Stock Plunges On Monday - Here's Why? - Morphic Holding (NASDAQ:MORF)

Since Friday, Morphic Therapeutic (NASDAQ: MORF) shares have plunged from $47.92 to $26.25 after the company announced the publication of an abstract discussing new EMERALD-1 phase 2a primary results at United 

25% of Patients Achieve Endoscopic Remission in Phase 2a EMERALD-1 Trial for MORF-057 - Vimarsana News

25% of Patients Achieve Endoscopic Remission in Phase 2a EMERALD-1 Trial for MORF-057

Data from the phase 2a trial showed 25.7% of patients with UC demonstrated endoscopic improvement and 45.7% achieved clinical response after week 12.